Drug intelligence / Profile preview

ELA stem cells

Development stage: Preclinical
Lead developer: Parcell Laboratories
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intranasal, Inhalation, Topical, Rectal, Ophthalmic, Intravenous, Intrathecal, Intraarticular, Perineural, Intra-urethral, Intra-arterial, Intracerebral, Intracord, Intraventricular, Subarachnoid, Intratumoral, Intracoronary, Transendocardial, Transpericardial, Perianal, Intraperitoneal

Overview

ELA stem cells are proprietary osteoprogenitor cells isolated from healthy adult donors. Developed by Parcell Spine, these cells are intended to improve spinal fusion rates for the treatment of spinal disorders. The product originated from Brigham and Women's Hospital and was licensed to Alphatec Spine for exclusive global distribution, with an anticipated launch in the second half of 2010.

Beyond the preview

Go deeper on ELA stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELA stem cells.

Explore the full profile